Eltrombopag to raise low platelets after chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can participate in the study consent and follow-up.
- You have chemotherapy-related thrombocytopenia (low platelets) that did not improve after repeat treatment with TPO or IL-11 medicines.
- You have stopped chemotherapy or radiation for more than 1 month.
- Your platelet count is under 30, and you have a bleeding tendency (bleeding risk).
- Your liver and kidney tests are not too abnormal (less than 1.5× the lab’s normal limit).
- You are able to use effective birth control; if you could become pregnant, your pregnancy test must be negative.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
Hear when a new Chemotherapy Induced Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.